{"id":1314,"date":"2025-06-23T21:08:32","date_gmt":"2025-06-23T21:08:32","guid":{"rendered":"http:\/\/www.vecimasupport.com\/?p=1314"},"modified":"2025-06-24T00:33:34","modified_gmt":"2025-06-24T00:33:34","slug":"experimental-drug-helps-patients-lose-nearly-a-quarter-of-body-weight-in-early-trials","status":"publish","type":"post","link":"http:\/\/www.vecimasupport.com\/index.php\/2025\/06\/23\/experimental-drug-helps-patients-lose-nearly-a-quarter-of-body-weight-in-early-trials\/","title":{"rendered":"Experimental drug helps patients lose nearly a quarter of body weight in early trials"},"content":{"rendered":"

An experimental weight-loss medication<\/a> was shown to help people lose nearly 25% of their body weight in early-stage 1a\/2b trials.<\/p>\n

The drug, amycretin \u2014 developed by Novo Nordisk \u2014 works by replicating two hunger hormones \u2014 amylin, which regulates appetite and creates a feeling of fullness, and glucagon-like peptide 1 (GLP-1), the same hormone that is used in Ozempic and Wegovy to suppress appetite and boost insulin secretion<\/a>.<\/p>\n

“Amycretin is the first treatment to harness the two distinct biological pathways stimulated by amylin and GLP-1 in a single molecule,” Martin Holst Lange, executive vice president and head of development at Novo Nordisk, previously said in a statement sent to Fox News Digital.<\/p>\n

GRANDFATHER’S SIMPLE CHANGES REVERSED PRE-DIABETES DIAGNOSIS THAT LEFT HIM ‘PETRIFIED’<\/u><\/strong><\/a><\/p>\n

In the study, which included 125 overweight or obese adults, participants who received weekly injections<\/a> of amycretin lost more weight than those who took a placebo, according to a press release from Novo Nordisk.<\/p>\n

Those who got the highest doses (up to 60 mg) lost up to 24.3% pounds after 36 weeks, compared to just 1.1% for the placebo group, per the release.<\/p>\n

A previous phase 1 trial of the oral (pill) version of amycretin also showed that treatment was “safe and tolerable,” with an “observed reduction in body weight” compared to placebo, the company stated.<\/p>\n

Taking the pill once a day led to around 10% weight loss<\/a>, and those who doubled the dose lost 13%.<\/p>\n

YOUR DNA COULD BE STOPPING YOU FROM LOSING WEIGHT, NEW STUDY SUGGESTS<\/u><\/strong><\/a><\/p>\n

Another benefit the researchers highlighted is that people taking amycretin did not appear to hit a “weight-loss plateau,” continuing to shed pounds as long as they took it.<\/p>\n

“The lack of weight loss plateauing indicates the possibility of achieving further weight reductions with extended treatment<\/a>,” Agnes Gasoirek, a senior clinical pharmacology specialist at Novo Nordisk, wrote in the phase 1 study findings.<\/p>\n

Novo Nordisk presented the latest findings at the American Diabetes Association in Chicago on June 22; they were also published in the medical journal Lancet.<\/p>\n

“We are pleased with the promising results of amycretin and the feedback from regulatory authorities and are excited to advance both subcutaneous and oral versions of this molecule into phase 3 development for weight management,” said Martin Holst Lange, executive vice president for Development at Novo Nordisk, in the release.\u00a0<\/p>\n

“These results reflect our robust pipeline in obesity, [and] our focus on progressing scientific innovation and expanding the range of options available to patients and healthcare professionals.”<\/p>\n

The most common side effects of amycretin, similar to other GLP-1s, were gastrointestinal symptoms<\/a> \u2014 primarily nausea, vomiting and decreased appetite.<\/p>\n

Adverse events were “mild to moderate” in severity, according to researchers. More frequent doses resulted in greater side effects.<\/p>\n

It\u2019s important to monitor these side effects closely, experts advise, as GI issues are common among patients with obesity<\/a>.\u00a0<\/p>\n

“While the initial weight-loss outcomes are indeed encouraging, further studies are needed to ensure that the therapeutic benefits consistently outweigh the potential risks, especially with long-term administration,” Dr. Christine Ren-Fielding, director and chief of bariatric surgery<\/a> at the NYU Langone Weight Management Program, previously told Fox News Digital.<\/p>\n

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER<\/u><\/strong><\/a><\/p>\n

While GLP-1-based drugs \u2014 including this new experimental pill \u2014 may show promising results, Ren-Fielding, who was not involved in the study, emphasized that they\u2019re “not a cure-all for obesity.”<\/p>\n

“Obesity is a chronic, multifactorial disease that requires a comprehensive, long-term approach,” she said at the time.<\/p>\n

For more Health articles, visit\u00a0<\/u><\/strong><\/i><\/a>www.foxnews.com\/health<\/u><\/strong><\/i><\/a><\/p>\n

“Pharmacological treatments can play a significant role in managing the condition, but they are often most effective when combined with other interventions<\/a>.”<\/p>\n

Next, Novo Nordisk plans to prepare for phase 3 trials of the medication, in both oral and injectable forms, for the management of obesity.<\/p>\n","protected":false},"excerpt":{"rendered":"

An experimental weight-loss medication was shown to help people lose nearly 25% of their body weight in early-stage 1a\/2b trials. The drug, amycretin \u2014 developed by Novo Nordisk \u2014 works by replicating two hunger hormones \u2014 amylin, which regulates appetite and creates a feeling of fullness, and glucagon-like peptide 1 (GLP-1), the same hormone that […]<\/p>\n","protected":false},"author":1,"featured_media":502,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[9],"tags":[],"_links":{"self":[{"href":"http:\/\/www.vecimasupport.com\/index.php\/wp-json\/wp\/v2\/posts\/1314"}],"collection":[{"href":"http:\/\/www.vecimasupport.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.vecimasupport.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.vecimasupport.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.vecimasupport.com\/index.php\/wp-json\/wp\/v2\/comments?post=1314"}],"version-history":[{"count":1,"href":"http:\/\/www.vecimasupport.com\/index.php\/wp-json\/wp\/v2\/posts\/1314\/revisions"}],"predecessor-version":[{"id":1315,"href":"http:\/\/www.vecimasupport.com\/index.php\/wp-json\/wp\/v2\/posts\/1314\/revisions\/1315"}],"wp:featuredmedia":[{"embeddable":true,"href":"http:\/\/www.vecimasupport.com\/index.php\/wp-json\/wp\/v2\/media\/502"}],"wp:attachment":[{"href":"http:\/\/www.vecimasupport.com\/index.php\/wp-json\/wp\/v2\/media?parent=1314"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.vecimasupport.com\/index.php\/wp-json\/wp\/v2\/categories?post=1314"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.vecimasupport.com\/index.php\/wp-json\/wp\/v2\/tags?post=1314"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}